SG Americas Securities LLC Increases Stock Holdings in Medpace Holdings, Inc. $MEDP

SG Americas Securities LLC lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 560.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,130 shares of the company’s stock after purchasing an additional 5,202 shares during the quarter. SG Americas Securities LLC’s holdings in Medpace were worth $3,152,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of MEDP. Geneos Wealth Management Inc. increased its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the period. Employees Retirement System of Texas purchased a new stake in shares of Medpace in the second quarter valued at about $36,000. IFP Advisors Inc boosted its holdings in shares of Medpace by 223.3% in the second quarter. IFP Advisors Inc now owns 194 shares of the company’s stock valued at $61,000 after acquiring an additional 134 shares in the last quarter. Hantz Financial Services Inc. raised its holdings in Medpace by 5,075.0% during the second quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock worth $65,000 after purchasing an additional 203 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC raised its holdings in Medpace by 514.3% during the second quarter. Cary Street Partners Investment Advisory LLC now owns 215 shares of the company’s stock worth $67,000 after purchasing an additional 180 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Price Performance

NASDAQ MEDP opened at $599.21 on Tuesday. The business has a 50 day moving average price of $581.15 and a 200 day moving average price of $504.33. The company has a market capitalization of $16.88 billion, a P/E ratio of 41.90, a PEG ratio of 2.00 and a beta of 1.43. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $626.26.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. During the same quarter in the prior year, the company earned $3.01 earnings per share. Medpace’s revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on MEDP shares. BMO Capital Markets assumed coverage on Medpace in a report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price objective on the stock. Barclays lifted their price target on Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Zacks Research upgraded Medpace from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 27th. Cowen reissued a “sell” rating on shares of Medpace in a report on Friday, October 24th. Finally, TD Cowen upped their price target on shares of Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research note on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have given a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $491.27.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 668 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total transaction of $394,580.92. Following the completion of the transaction, the chief executive officer directly owned 646,184 shares in the company, valued at approximately $381,694,426.96. This trade represents a 0.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Kevin M. Brady sold 3,000 shares of the company’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the completion of the sale, the chief financial officer directly owned 6,000 shares in the company, valued at $3,542,100. This trade represents a 33.33% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 387,925 shares of company stock valued at $233,386,647. Insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.